Abstract

BackgroundFrontotemporal lobar degeneration (FTLD) consists of a clinically and neuropathologically heterogeneous group of syndromes affecting the frontal and temporal lobes of the brain. Mutations in microtubule-associated protein tau (MAPT), progranulin (PGRN) and charged multi-vesicular body protein 2B (CHMP2B) are associated with familial forms of the disease. The prevalence of these mutations varies between populations. The H1 haplotype of MAPT has been found to be closely associated with tauopathies and with sporadic FTLD. Our aim was to investigate MAPT mutations and haplotype frequencies in a clinical series of patients with FTLD in Northern Finland.MethodsMAPT exons 1, 2 and 9–13 were sequenced in 59 patients with FTLD, and MAPT haplotypes were analysed in these patients, 122 patients with early onset Alzheimer's disease (eoAD) and 198 healthy controls.ResultsNo pathogenic mutations were found. The H2 allele frequency was 11.0% (P = 0.028) in the FTLD patients, 9.8% (P = 0.029) in the eoAD patients and 5.3% in the controls. The H2 allele was especially clustered in patients with a positive family history (P = 0.011) but did not lower the age at onset of the disease. The ApoE4 allele frequency was significantly increased in the patients with eoAD and in those with FTLD.ConclusionWe conclude that although pathogenic MAPT mutations are rare in Northern Finland, the MAPT H2 allele may be associated with increased risks of FTLD and eoAD in the Finnish population.

Highlights

  • Frontotemporal lobar degeneration (FTLD) consists of a clinically and neuropathologically heterogeneous group of syndromes affecting the frontal and temporal lobes of the brain

  • We sequenced exons 1, 2 and 9–13 of the microtubule-associated protein tau (MAPT) gene in 59 Finnish patients with FTLD and analysed MAPT haplotypes in these patients, 122 patients with early onset Alzheimer's disease (eoAD) and 198 middle-aged healthy controls

  • No pathogenic MAPT mutations were found in the patients with FTLD

Read more

Summary

Introduction

Frontotemporal lobar degeneration (FTLD) consists of a clinically and neuropathologically heterogeneous group of syndromes affecting the frontal and temporal lobes of the brain. Mutations in microtubule-associated protein tau (MAPT), progranulin (PGRN) and charged multi-vesicular body protein 2B (CHMP2B) are associated with familial forms of the disease. The prevalence of these mutations varies between populations. The main clinical syndromes are frontotemporal dementia (FTD), semantic dementia (SD) and progressive non-fluent aphasia (PA).[1] FTLD can be divided neuropathologically into diseases with tau-positive inclusions and diseases with tau-negative and ubiquitin-positive inclusions.[2] A positive family history is present in 30– 50% of FTLD cases.[3,4] Mutations in microtubule-associated protein tau (MAPT), progranulin (PGRN) and charged multi-vesicular body protein 2B (CHMP2B) are associated with the autosomal dominant form of the disease. The predominant haplotype, H1, has been found to be associated with sporadic tauopathies, [16,17,18] and to have a faint association with FTLD.[19,20] in some studies the H2 haplotype has been found to be associated with FTLD.[15,21]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call